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Abstract Recent studies have highlighted that Acti-
vin A, a member of the transforming growth factor-b
(TGF-b) superfamily, may be involved in the regula-
tion of osteoblastic activity and in osteoclast differen-
tiation. Therefore, we have investigated the clinical
significance of its circulating levels in patients with
bone metastasis. Activin A serum concentrations were
determined, by a commercially available enzyme-
linked immunosorbent assay kit, in 72 patients with
breast cancer (BC) or prostatic cancer (PC) with
(BM+) or without (BM–) bone metastases, in 15 fe-
male patients with age-related osteoporosis (OP), in 20
patients with benign prostatic hypertrophy (BPH) and
in 48 registered healthy blood donors (HS) of both sex
(25 female and 23 male). Activin A serum concentra-
tions were significantly increased in BC or PC patients
as compared to OP (P < 0.0001) or BPH (P = 0.045),
respectively, or to sex matched HS (P < 0.0001).
Additionally, these levels resulted more elevated in PC
patients as compared to BC patients (P = 0.032).
Interestingly, Activin A was significantly higher in
BM+ patients than in BM– patients (BC, P = 0.047;
PC, P = 0.016). In BC patients, a significant correlation
was observed only between Activin A and number of
bone metastases (P = 0.0065) while, in PC patients,
Activin A levels were strongly correlated with the
Gleason score (P = 0.011) or PSA levels (P = 0.0001)
and, to a lessen extent, with the number of bone
metastases (P = 0.056). Receiver operating character-
istic curve (ROC) analysis showed a fair diagnostic
accuracy of Activin A to discriminate between BM+
and BM– patients (BC: AUC = 0.71 ± 0.09, P = 0.03;
PC: AUC = 0.73 ± 0.081, P = 0.005). These findings
indicate that Activin A may be implicated in the
pathogenesis of bone metastasis. Therefore, this cyto-
kine may be considered a novel potential target for a
more selective therapeutic approach in the treatment
of skeletal metastasis and may be also useful as
additional biochemical marker of metastatic bone
disease.
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Introduction
Activin A is a member of the transforming growth
factor-b (TGF-b) superfamily, which comprises a
group of growth factors with similar structure but dif-
ferent functions [1–3]. It was originally identified as an
endocrine derived regulator of pituitary follicular
stimulating hormone (FSH) [1, 2]. However, sub-
sequent studies have shown that this multifunctional
cytokine is widely distributed in different cells and
tissues and that it appears to be actively involved in the
regulation of several important biological functions
such as cell proliferation, apoptosis, differentiation,
immune response, wound healing, embryogenesis,
endocrine functions, tissue metabolism and homeo-
stasis [1–8]. The biological effects of Activin A, are
mediated through two transmembrane serine/threo-
nine receptor kinases namely, ActRI and ActRII and
may be inhibited by a number of Activin binding
proteins [1, 2, 9]. Interestingly, a consistent number of
experimental and clinical observations have reported
that many human cancers present altered expression
levels of Activin A and/or altered levels of its receptors
and/or that of its specific inhibitors and that these
alterations may be associated with a more malignant
tumor phenotype [3, 4, 10–20]. Furthermore, recent
findings have shown that, Activin A may play an active
role in the modulation of osteoblastic activity and in
osteoclast differentiation during bone remodeling
processes associated to a number of physiological or
pathological conditions [1, 5–8, 10, 21, 22]. Therefore, it
has been hypothesized that this growth factor may play
also a role in bone metastasis formation [10]. On the
basis of these considerations we have undertaken some
studies to assess the clinical significance of the circu-
lating levels of Activin A in patients with breast (BC)
or prostate cancer (PC) as these tumors preferentially
metastasize to the bone and induce the formation of
osteolytic and/or osteoblastic metastasis, respectively
[23].
Patients and methods
The study included 48 registered healthy blood donors
(HS) of both sex (25 female and 23 male) who served
as control group, 15 female patients with age-related
osteoporosis (OP) (mean age 74.1 ± 10.5 years), 20
patients with histological confirmed benign prostate
hypertrophy (BPH) (mean age 64.0 ± 6.7 years) and
72 patients with breast cancer (mean age 57.7 ±
10.2 years) or prostate cancer (mean age 71.03 ±
8.1 years) with confined disease (BM–) or skeletal
metastasis only (BM+). The main characteristics of
cancer patients are reported in Table 2. Bone metas-
tases were diagnosed by skeletal scintigraphy and/or
skeleton X-ray or, where required, by magnetic reso-
nance imaging. None of the metastatic patients had
documented extraskeletal lesions. The study was ap-
proved by local ethical committee and carried out in
accordance with the Declaration of Helsinki [24].
Activin A assay
Blood samples from cancer patients or patients with
OP or BPH were obtained before starting any ther-
apy. The samples were drawn into polycarbonate
tubes, allowed to clot at room temperature and then
centrifuged at 3,500 rpm for 15 min (Hereus Omni-
fuge 2.0 RS, Hereus Sepatech). Serum aliquots were
stored at –80C until assays. Activin A serum con-
centrations were determined by a commercially
available two-step sandwich enzyme-linked immuno-
sorbent assay (ELISA) kit according the manufac-
turer’s instructions (Activin A Assay kit, Serotec,
Oxford Bio-Innovation Ltd, UK). The reported
detection limit was < 78 pg/ml. According to the
manufacturer the assay has no detectable cross reac-
tivity with Inhibin A, Follistatin, Activin B, or Inhibin
B while a small cross reaction (1–5%) may be
observed with Activin AB.
Serum tumor markers
The serum levels of tumor marker Ca15.3 were addi-
tionally measured in BC and OP patients while PSA
levels were determined in PC and BPH patients. Both
markers were determined by commercially available
immunoluminometric assays kits (DiaSorin, Germany).
The reference values and the detection limits reported
by the manufacturer were 30 U/ml and < 0.3U/ml for
Ca15.3 and 3.2 ng/ml and < 0.009 ng/ml for PSA,
respectively.
Statistical analysis
Statistical analysis was performed by using the Med-
calc 7.4 statistical software package (Medcalc Mari-
akerke, Belgium) (MEDCALC version 7.4 Copyright
1993–2004, Frank Schoonjans http://www.medcalc.be).
Data were tested for normal distribution by the
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Kolmogorov–Smirnov test. Because of their uneven
distribution the statistical analysis was performed,
where required, by the non-parametric Mann–Whit-
ney U test, the Kruskall–Wallis test of variance and
the Spearman rank correlation test (rs). The receiver
operating characteristic curve (ROC) was generated
to assess the sensitivity and the specificity of serum
Activin A for detection of bone metastasis.
Results
Activin A serum levels in HS, OP, BPH, BC and PC
patients are shown in Table 1. No gender related dif-
ference in the serum concentrations of Activin A were
observed in HS. The circulating levels of this growth
factor were significantly increased in BC or BC pa-
tients as compared to OP patients (P < 0.0001) or
BPH patients (P = 0.045), respectively, or to sex mat-
ched HS (P < 0.0001). Significant differences were
also highlighted between BPH patients and HS
(P = 0.0065) (Table 1). Interestingly, Activin A serum
levels were more elevated in PC patients as compared
to BC patients (P = 0.032) (Table 1) and were also
significantly higher in BC or PC patients with bone
metastasis as compared to patients with confined dis-
ease (BC, P = 0.047; PC, P = 0.016) (Fig. 1). Table 2
shows the distribution of serum Activin A in BC or PC
patients according to some clinicobiological parame-
ters. In BC patients, Activin A concentrations signifi-
cantly correlated only with the number of bone
metastases (P = 0.0065) while, in PC patients Activin
A levels were significantly associated with the Gleason
score (P = 0.011) or PSA levels (P = 0.0001) and
weakly with the number of bone lesions (P = 0.056)
(Table 2). ROC curve analysis was performed to assess
the effectiveness of serum Activin A to discriminate
between cancer patients with bone metastases from
those without bone metastases. At the cut-off level
determined by ROC curve, Activin A showed a fair
diagnostic accuracy to discriminate between BM+ and
BM– patients (BC: AUC = 0.71 ± 0.09, 95% CI: 0.52–
0.85, P = 0.03; PC: AUC = 0.73 ± 0.081, 95% CI: 0.56–
0.86, P = 0.005) (Fig. 2). However, in our series of
patients, serum markers Ca15.3 and PSA showed a
better diagnostic performance (Table 3). In BC pa-
tients, the combination of Activin A with Ca15.3, at the
cut-off levels considered in this study, resulted in a
lower sensitivity (50%) and in a higher specificity
(100%) if compared to Ca15.3 alone (Table 3) while, in
PC patients, Activin A did not substantially affect the
good diagnostic performance of PSA alone in detecting
BM+ patients (Table 3).
Conclusions
Several studies suggest that Activin A may have a
role in tumor progression [2, 3, 10–25]. The specific
Table 1 Activin A serum concentrations (ng/ml) in healthy
subjects and in patients with non-malignant or malignant
diseases
No of
subjects
Median Range Mean ± SD
Healthy subjects 48 0.41 0.10–0.82 0.43 ± 0.17
Female 25 0.42 0.22–0.60 0.43 ± 0.12
Male 23 0.40 0.10–0.82 0.44 ± 0.21
Primary osteoporosis 15 0.38 0.22–0.59 0.37 ± 0.09
Benign prostatic
hyperplasia
20 0.68 0.37–1.34 0.67 ± 0.26ª
Breast cancer 33 0.60 0.33–4.79 0.92 ± 0.94b,c
Prostate cancer 39 0.80 0.23–3.33 1.03 ± 0.70b,d,e
Data analysis was computed by the Mann–Whitney U test;
aP = 0.0002 and bP < 0.0001 vs HS; cP < 0.0001 vs OP;
dP = 0.045 vs BPH; eP = 0.032 vs BC
Fig. 1 Activin A serum
distribution in breast or
prostate cancer patients with
(BM+) or without (BM–)
bone metastases
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mechanisms by which this growth factor may facilitate
this phenomenon have still not fully understood. In
vitro studies have shown that Activin A can stimulate
or inhibit tumor cell proliferation according to the
tumor type [2–4]. Therefore, in tumor in which
Activin A has a growth inhibitory activity, in order to
proliferate the tumor cell must acquire resistance to
this growth factor. Conversely, in tumor in which
Activin A stimulate, tumor cell proliferation, a sus-
tained Activin A signaling would promote tumor
growth [2–4]. Some experimental studies, have indi-
cated that these effects may occur in tumor cells fol-
lowing the disregulation of Activin signaling pathway
caused by alterations in the expression levels of this
cytokine and/or in that of its receptors and/or inhibitors
or following loss or mutations of specific genes codify-
ing for its receptors [2, 3, 10, 11–18, 21, 27–29]. The
possible correlation between these mechanisms and
tumor progression is corroborated by a number exper-
imental and clinical observations which have high-
lighted that these alterations may be present in several
neoplasms including breast and prostate cancer and are
associated with more aggressive forms of these neo-
plastic diseases [2–4, 10–19, 25–29]. Furthermore, in
vitro studies indicate that this growth factor, in addi-
tion to its effects on cell proliferation, apoptosis and
malignant transformation, may also facilitate the
homing and spread of tumor cells in several organs
including the bone [3, 7, 10, 21, 30, 31]. Our results
appear to support this hypothesis. In fact, it has been
shown that (i) Activin A circulating levels were sig-
nificantly increased in cancer patients as compared to
healthy subjects or patients with benign diseases; (ii)
BC or PC patients with bone metastases had serum
concentrations of Activin A significantly higher than
those measured in patients with confined diseases; (iii)
in both BC and PC patients, the serum levels of this
growth factor were positively associated with the
number of skeletal metastases. Furthermore, mean
Activin A serum concentrations were significantly
more elevated in PC patients than in BC patients. This
latter phenomenon further indicate, as reported in
other studies, that Activin A may be actively involved
in the modulation of the osteoblastic activity which, in
the case of prostate cancer, is predominant and may
account for osteoblastic reactions induced by tumor
cells [8, 12, 23, 31, 32]. In addition, our results have
highlighted that, in PC patients Activin A levels sig-
nificantly correlated with PSA serum concentrations.
These data may fit well with the results from in vitro
studies of Fujii et al. [33] which have shown that
Activin A upregulates PSA gene expression and in-
creases the secretion of this serine proteinase in
LNCaP cells. On the other hand, the significant cor-
relation of Activin A with the Gleason score further
confirm previous immunohistochemical observations
of Cardillo et al. [34] on the positive correlation be-
tween Activin A overexpression and more aggressive
forms of this tumor. Finally, ROC curve analysis
showed a fair diagnostic accuracy of Activin A to de-
tect patients with bone metastasis. However, in our
series of patients, its diagnostic performance did not
result significantly superior to those of PSA or Ca15.3.
Nevertheless, the combination of Activin A with
Ca15.3, at the cut-off level considered in this study,
correctly identified 100% of BC patients without bone
Table 2 Activin A distribution in patients with breast or
prostate cancer according to some clinicobiological parameters
No. pts (%) Activin A
(ng/ml)
P value
Breast cancer
Tumor size
T1 8 (24.2%) 0.56
T2 18 (54.5) 0.66 0.099(N.S.)a
T3-T4 7 (21.8) 0.93
Tumor grade
G1 7 (21.8) 0.53
G2 16 (48.5) 0.60 0.081 (N.S.)ª
G3 10 (30.3) 0.88
Estrogen receptors
Negative 6 (20) 0.56
Positive 24 (80) 0.66 0.83 (N.S.)b
Progesteron receptors
Negative 23 (79.3) 0.56
Positive 6 (20.7) 0.83 0.12 (N.S.)b
Ca15.3
< 30 U/ml 21 (65.6%) 0.55
> 30 U/ml 11 (35.4) 0.72 0.17 (N.S.)b
Number of metastases
M0 19 (57.6) 0.55
M1-3 7 (21.2) 0.60 0.0065ª
M > 3 7 (21.2) 1.8
Prostate cancer
Tumor size n.d.d
Gleason score
2–4 8 (20.5) 0.57
5–7 22 (56.4) 0.83 0.011ª
8–10 9 (23.1) 1.40
PSA
£ 4 ng/ml 10 (27.0) 0.56
> 4 ng/ml < 10 ng/ml 9 (24.3) 0.63 < 0.0001ª
> 10 ng/ml 18 (48.7) 0.89
Number of metastases
M0 16 (41.0) 0.59
M1-3 4 (10.3) 0.81 0.056ª (N.S.)
M > 3 1 9 (48.7) 0.94
N.S., not significant; n.d., not determined; ªKruskall–Wallis test;
bMann–Whitney U test
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metastases while, the combination of Activin A and
PSA did non-substantially affect the diagnostic per-
formance of this latter tumor marker. In conclusion,
the present investigations suggest that Activin A may
be implicated in bone metastasis formation from breast
or prostate cancer. Therefore, this growth factor may
be considered a novel potential target for a more
effective therapeutic approach in the treatment of bone
metastasis. On the other hand, further studies with a
wider number of patients may better define the clinical
role of Activin A as additional biochemical marker of
metastatic bone disease.
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